🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. QMF149

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule active

    1 trial

  2. QMF149 150/80 μg

    Novartis Pharmaceuticals

    Mild Asthma

    phase 3 small molecule completed

    1 trial

  3. QRX003

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    1 trial

  4. QRX003, 4% Lotion

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    2 trials

  5. QRX003-2% Lotion

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    1 trial

  6. QVA149

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  7. QVM149 150/50/160

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  8. Qarziba 4.5 mg/mL concentrate for solution for infusion

    COLLEGIUM PHARMACEUTICAL, INC

    Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment.

    phase 3 small molecule active

    1 trial

  9. Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch

    Lacuna Pharma Pty Ltd

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial

  10. RAD001

    Novartis Pharmaceuticals

    Tuberous Sclerosis Complex-associated Refractory Seizures

    phase 3 small molecule completed

    1 trial

  11. RANOLAZINE, FLECARDIA Διάλυμα για ένεση/έχχυση

    Lacuna Pharma Pty Ltd

    Restoration of sinus rhythm in patients with recent AF onset

    phase 3 small molecule active

    1 trial

  12. RAPIBLOC 300 mg, poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  13. REC-2282

    RECURSION PHARMACEUTICALS, INC.

    Neurofibromatosis Type 2

    phase 3 small molecule terminated

    1 trial

  14. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  15. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  16. REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion, NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  17. RHB-102

    RedHill Biopharma

    Gastroenteritis

    phase 3 small molecule completed

    1 trial

  18. RHB-104

    RedHill Biopharma

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  19. RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

    RedHill Biopharma

    Crohn Disease

    phase 3 small molecule completed

    1 trial

  20. RHB-105

    RedHill Biopharma

    Dyspepsia

    phase 3 small molecule completed

    1 trial

  21. RHB-105

    RedHill Biopharma

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  22. RHB-204

    RedHill Biopharma

    Pulmonary Mycobacterium Avium Complex Infection

    phase 3 small molecule terminated

    1 trial

  23. RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  24. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources